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Chlorpyrifos (CPF), one of the most widely
used organophosphate pesticides, has under-
gone increased restriction of use in the United
States because of developmental neurotoxicity
[U.S. Environmental Protection Agency
(EPA) 2000, 2002]. Many animal studies
have focused on long-term cholinergic deﬁcits
and related behaviors, given the acknowledged
role of cholinesterase inhibition and choliner-
gic hyperstimulation in the systemic toxicity
of organophosphates (Barone et al. 2000;
Clegg and van Gemert 1999a, 1999b;
Mileson et al. 1998; Pope 1999; Slotkin 1999,
2004). However, in the developing brain,
CPF affects many of the basic processes of
neural cell development through mechanisms
that are not reﬂective of cholinesterase inhibi-
tion or cholinergic mechanisms, eliciting
widespread disruption of neural cell replica-
tion and differentiation, axonogenesis and
synaptogenesis, and synaptic function (Barone
et al. 2000; Casida and Quistad 2004; Gupta
2004; Pope 1999; Slotkin 1999, 2004).
Importantly, most of these effects are seen at
CPF exposures below the threshold for sys-
temic toxicity and even below the threshold
for cholinesterase inhibition (Barone et al.
2000; Casida and Quistad 2004; Gupta 2004;
Pope 1999; Qiao et al. 2002, 2003; Schuh
et al. 2002; Slotkin 1999, 2004) and are
major contributors to persistent neuro-
behavioral defects (Icenogle et al. 2004; Levin
et al. 2001, 2002).
In fact, long-term alterations after fetal or
neonatal CPF exposure are not confined to
cholinergic systems but rather involve a wide
variety of neurotransmitters and, notably,
serotonin (5HT) (Aldridge et al. 2003, 2004;
Dam et al. 1999; Raines et al. 2001; Slotkin
1999, 2004; Slotkin et al. 2002). Deﬁciencies
in 5HT systems are a hallmark of human
depression, and the most effective therapies
use drugs designed to restore 5HT synaptic
function (Maes and Meltzer 1995). In the
present study, we evaluated the effects of
neonatal CPF exposure on behaviors in adult-
hood that are well established in animal mod-
els of depression to reflect 5HT synaptic
dysfunction (Cairncross 1984; Cryan et al.
1999; Harkin et al. 1999; Jesberger and
Richardson 1985; Kelly et al. 1997; Leonard
and Tuite 1981; Richardson 1991; Slotkin
et al. 1999). In the elevated plus maze, a
decrease in 5HT input suppresses the normal
adaptive fear response (Kusserow et al. 2004),
thereby increasing the amount of time spent
in the open arms, an effect reversed by admin-
istration of 5HT agonists or 5HT reuptake
inhibitors (Kelly et al. 1997; Mar et al. 2000;
Martin et al. 1998; McGrath and Norman
1999). Similarly, anhedonia can be tested by
the loss of preference for chocolate milk com-
pared with water (Cairncross 1984; Jesberger
and Richardson 1985; Kelly et al. 1997;
Leonard and Tuite 1981; Pucilowski et al.
1993; Richardson 1991; Slotkin et al. 1999),
a response that again is typical of a deﬁcit in
5HT function (Juckel et al. 2003). Finally,
because neonatal CPF exposure has persistent
effects on cognitive function (Icenogle et al.
2004; Levin et al. 2001, 2002), we evaluated
learning and memory in the 16-arm radial
maze (Icenogle et al. 2004; Levin et al. 2001,
2002), assessing both basal performance and
the effects of a pharmacologic challenge with a
5HT2 antagonist, ketanserin, to establish a
mechanistic link between effects on 5HT and
resultant cognitive alterations. Studies were
conducted after CPF exposure of neonatal rats
on postnatal days (PND)1–4, a period of
heightened sensitivity to long-term effects on
biomarkers of 5HT synaptic function
(Aldridge et al. 2003, 2004).
Materials and Methods
Animal treatments. All experiments were
carried out in accordance with the Guide for
the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources
1996) as adopted and promulgated by the
National Institutes of Health. Timed-pregnant
Sprague-Dawley rats (Charles River, Raleigh,
NC) were housed in breeding cages, with a
12-hr light/dark cycle and free access to food
and water. On the day of birth, all pups were
randomized and redistributed to the dams
with a litter size of 10 to maintain a standard
nutritional status. Randomization within the
respective treatment groups was repeated at
intervals of several days; in addition, dams
were rotated among litters to distribute any
maternal caretaking differences randomly
across litters and treatment groups. CPF
(Chem Service, West Chester, PA) was
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Developmental exposure to chlorpyrifos (CPF) causes persistent changes in serotonergic (5HT)
systems. We administered 1 mg/kg/day CPF to rats on postnatal days 1–4, a regimen below the
threshold for systemic toxicity. When tested in adulthood, CPF-exposed animals showed abnor-
malities in behavioral tests that involve 5HT mechanisms. In the elevated plus maze, males treated
with CPF spent more time in the open arms, an effect seen with 5HT deﬁciencies in animal mod-
els of depression. Similarly, in an anhedonia test, the CPF-exposed group showed a decreased pref-
erence for chocolate milk versus water. Developmental CPF exposure also has lasting effects on
cognitive function. We replicated our earlier ﬁnding that developmental CPF exposure ablates the
normal sex differences in 16-arm radial maze learning and memory: during acquisition training,
control male rats typically perform more accurately than do control females, but CPF treatment
eliminated this normal sex difference. Females exposed to CPF showed a reduction in working and
reference memory errors down to the rate of control males. Conversely, CPF-exposed males exhib-
ited an increase in working and reference memory errors. After radial-arm acquisition training, we
assessed the role of 5HT by challenging the animals with the 5HT2 receptor antagonist ketanserin.
Ketanserin did not affect performance in controls but elicited dose-dependent increases in working
and reference memory errors in the CPF group, indicating an abnormal dependence on 5HT sys-
tems. Our results indicate that neonatal CPF exposures, classically thought to be subtoxic, produce
lasting changes in 5HT-related behaviors that resemble animal models of depression. Key words:
animal models, behavioral deﬁcits, brain development, chlorpyrifos, depression, organophosphates,
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http://dx.doi.org/ [Online 2 February 2005]dissolved in dimethylsulfoxide to provide
consistent absorption (Whitney et al. 1995)
and was injected subcutaneously at a dose of
1 mg/kg in a volume of 1 mL/kg once daily
on PND1–4; control animals received equiva-
lent injections of the dimethylsulfoxide vehi-
cle. This regimen has been shown previously
to produce neurotoxicity in developing rat
brain, including lasting alterations in bio-
markers of 5HT synaptic function, without
eliciting growth retardation or any other signs
of systemic toxicity (Aldridge et al. 2003,
2004). Indeed, neonatal brain cholinesterase
inhibition is only about 25% (Song et al.
1997), well below the 70% threshold neces-
sary for symptoms of cholinergic hyperstimu-
lation (Clegg and van Gemert 1999a), thus
resembling the nonsymptomatic exposures
reported in pregnant women (De Peyster
et al. 1993). Moreover, the dose used here is
well within the range of typical fetal and
childhood exposures after routine application
(Gurunathan et al. 1998; Ostrea et al. 2002).
Animals were weaned on PND21.
All behavioral testing was carried out dur-
ing the dark phase, the most active period, but
in lighted environments so that the rats could
access the visual cues necessary to perform the
tasks. Tests were performed on nine rats per
sex per treatment group (36 animals in total),
using no more than one male and one female
from each litter. Beginning on PND47, the
light/dark cycle was shifted by 6 hr (lights on
at 0000 hr), and assessments were begun with
the elevated plus maze (PND52–53) and the
chocolate milk consumption test (PND54).
On PND57, the light/dark cycle was shifted an
additional 6 hr (lights on at 1800 hr), and
radial-arm maze training was conducted during
a 5-week period beginning on PND64.
Ketanserin challenges in the radial-arm maze
were undertaken in weeks 16–17. This
sequence was designed to permit multiple
behavioral tests to be conducted without signif-
icant carryover of effects from one test to the
next (Icenogle et al. 2004; Levin et al. 2001,
2002; Slotkin et al. 1999). Tests were video-
taped and scored by a trained observer who
was blinded to the animal treatments.
Elevated plus maze. The maze was con-
structed of black-painted wood with arms
55 cm long and 10.2 cm wide, placed
50.8 cm above the ﬂoor. Two opposed arms
had walls that were 15.2 cm tall, whereas the
other two arms, set at 90° to walled arms, had
smaller railings, only 2 cm tall. Rats were
placed in the center area and allowed to roam
freely for a total of 300 sec, and the time
spent in the different types of arms was
recorded, along with the number of times the
animals crossed the center.
Chocolate milk preference. One hour after
the start of the dark cycle, subjects were placed
in a novel cage without food available and were
presented with a choice of bottles containing
water or chocolate milk. Consumption of each
was measured after a single, 2-hr test session
(Pucilowski et al. 1993; Slotkin et al. 1999).
Radial-arm maze training. During the
period in which animals were trained in the
radial-arm maze, they had free access to water,
but food was restricted to approximately
15 g/day to provide an adequate stimulus to
seek the food reward they obtained in the
maze. The maze, made from black-painted
wood, had a central platform 50 cm in diame-
ter, elevated 30 cm from the ﬂoor, containing
sixteen 10 × 60 cm arms projecting radially,
each with a food cup 2 cm from the distal end.
Tests were conducted in a quiet room with
multiple extramaze visual cues that always
remained in the same locations relative to the
maze. The rats were familiarized with the food
reinforcement by placing each rat in an opaque
cylinder in the middle of the maze with a
sugar-coated cereal (Froot Loops halves;
Kellogg Co., Battle Creek, MI) and giving
them up to 5 min to eat all of the pieces.
Radial-arm maze training was then carried out
3 days/week for a total of 18 sessions per rat,
grouped into blocks of three consecutive ses-
sions for analysis. For each rat, the same
12 arms were baited at the beginning of each
session, leaving the same four arms always
unbaited; the array of baited and unbaited
arms differed among rats. To begin each ses-
sion, the rat was placed in an opaque cylinder
in the middle of the maze for 10 sec to allow
for orientation and to avoid bias as to which
arm would be entered first. Timing began
when the cylinder was removed, and the rat
was allowed to roam freely about the maze for
10 min or until all 12 baited arms had been
entered. Arm choice was recorded if all four
paws crossed the threshold of the arm, and a
note was made whether the reinforcement was
eaten. The arms were not rebaited, so repeated
entries into an arm were not rewarded and
were counted as errors of working memory
(Icenogle et al. 2004; Levin et al. 2001, 2002).
Entries into arms that were never baited were
recorded as reference memory errors. The
response latency (time per entry) was calcu-
lated by dividing the total time of the session
by the number of arms entered.
Ketanserin challenges in the radial-arm
maze. After the 18 sessions of radial-arm
maze training, the rats were tested by chal-
lenge with ketanserin, a 5HT2 receptor antag-
onist, to determine their reliance on 5HT
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Figure 1. Effects of neonatal CPF exposure on per-
formance in the elevated plus maze, presented as
the percentage of time spent in the open arms.
Data represent means and SEs. ANOVA indicated a
main effect of CPF treatment (p < 0.0005) and an
interaction of treatment × sex (p < 0.06). Separate
analyses were conducted for males and females,
showing a significant treatment effect only in
males (asterisk). Control males and females also
differ from each other signiﬁcantly (p < 0.008). 
Figure 2. Effects of neonatal CPF exposure on the
consumption of chocolate milk compared with
water. Data represent means and SEs of the ratio
of chocolate milk consumption to water during a
2-hr period. ANOVA indicates a main effect of CPF
(p < 0.02) without an interaction of treatment × sex,
so lower-order evaluations were not performed for
males and females.
14
12
10
8
6
4
2
1–3
E
r
r
o
r
s
4–6 7–9 10–12 13–15 16–18 1–3 4–6 7–9 10–12 13–15 16–18
Session Session
14
12
10
8
6
4
2
E
r
r
o
r
s
B A Control
CPF
Figure 3. Effects of neonatal CPF exposure on working memory errors in the 16-arm radial maze in (A) males
and (B) females. Values shown are means and SEs across groupings of three sessions. ANOVA indicated a
signiﬁcant treatment × sex interaction (p < 0.01), with the females showing a main treatment effect of CPF
(p < 0.02).mechanisms for memory. Twenty minutes
before the test session, ketanserin was admin-
istered at subcutaneous doses of 0, 0.5, 1, or
2 mg/kg in 1 mL/kg isotonic saline vehicle.
The different doses were given in a counter-
balanced order; that is, the sequence of doses
was randomized such that any one dose had
an equal probability of being given ﬁrst, sec-
ond, third, or fourth. Rats in both the control
and CPF groups and for each sex received the
challenge drug doses in all the different possi-
ble sequences, and at least two days elapsed
between testing with each subsequent dose.
Data analysis. Data are presented as
means and SEs. To establish the effects of
CPF and its relationship to other variables, a
multivariate analysis of variance (ANOVA;
data log-transformed whenever the variance
was heterogeneous) was first conducted,
encompassing neonatal treatment, sex, and,
where multiple evaluations were run on the
same animal (radial-arm maze, ketanserin
challenge), the repeated measure associated
with that test. Where CPF treatment inter-
acted with the other variables, data were then
subdivided to permit lower-order ANOVAs,
followed, where appropriate, by Fisher’s pro-
tected least significant difference to identify
individual values for which the CPF groups
differed from the corresponding control. For
all tests, signiﬁcance for main treatment effects
was assumed at p < 0.05; however, for inter-
actions at p < 0.1, we also examined whether
lower-order main effects were detectable after
subdivision of the interactive variables
(Snedecor and Cochran 1967).
Results
Elevated plus maze. In agreement with an
earlier report (Elliott et al. 2004), control
males spent a much shorter period in the
open arms of the plus maze than did females
(main effect of sex, p < 0.008; Figure 1). CPF
exposure had signiﬁcant, sex-selective effects,
raising the open-arm time in males to the
same level as found in females, whereas the
CPF-treated females showed no net difference
from their corresponding controls. A similar
pattern was seen for locomotor activity in the
plus maze, as assessed by the number of cen-
ter crossings: control males (4.6 ± 0.7 cross-
ings) were much less active than were control
females (8.7 ± 1.5, p < 0.03 vs. males), and
CPF exposure increased the male value
(8.2 ± 1.4, p < 0.04 vs. control males) to
match that of females, whereas females were
unaffected by CPF treatment (9.0 ± 1.0).
Chocolate milk preference. Control males
and females showed equivalent preference for
chocolate milk versus water in the anhedonia
test. CPF treatment produced a parallel
decrease in the preference ratio across both
sexes (main effect of CPF, p < 0.02; Figure 2).
There were no changes in total fluid con-
sumption during the 2-hr test period
(23 ± 1 mL for each group).
Radial-arm maze training. As identified
in previous studies (Icenogle et al. 2004;
Levin et al. 2001, 2002), there was a signiﬁ-
cant sex difference in the rate of working
memory errors during training in the radial-
arm maze, with control males showing consis-
tently fewer errors than did control females
(p < 0.008; Figure 3). The effects of CPF
exposure similarly showed strong sex depen-
dence (p < 0.01 for the interaction of treat-
ment × sex), reﬂecting a tendency to increase
the error rate in males but to decrease the rate
significantly in females. Accordingly, CPF
exposure effectively eliminated the normal,
characteristic sex difference in maze perfor-
mance (no signiﬁcant effect of sex in the CPF
group). These ﬁndings for the training stage
thus replicate previous ﬁndings in a separate
cohort of animals at somewhat younger ages
(Levin et al. 2001).
A similar pattern was seen for reference
memory errors, with a sex difference in the
control group (errors in males < females,
p < 0.008) but not in the animals exposed to
CPF. CPF treatment again evoked a signiﬁcant
sex-related alteration of performance (treat-
ment × sex, p < 0.004). The net effect of CPF
was to increase the error rate significantly in
males (Figure 4A) but to cause a decrease in
females that was at the margin of signiﬁcance
(Figure 4B). ANOVA across both working and
reference memory errors confirmed that the
net increase in error rate in males and decrease
in females were both signiﬁcant (p < 0.05 and
p < 0.007, respectively).
In contrast to the effects of CPF on work-
ing and reference memory errors, there were
no alterations in latency (time per arm entry;
data not shown).
Ketanserin challenges in the radial arm
maze. Despite the differences during acquisi-
tion, CPF-exposed animals achieved error
rates similar to those of controls by the end of
the 18 training sessions. At that point, animals
were challenged with ketanserin to evaluate
the contributions of 5HT2 receptor activity to
memory. At the doses used, ketanserin chal-
lenge did not cause any amnestic effect in con-
trol rats: neither working (Figure 5A) nor
reference (Figure 5B) memory error rates were
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Figure 4. Effects of neonatal CPF exposure on reference memory errors (means and SEs) in the 16-arm
radial maze in (A) males and (B) females. Values shown are means and SEs across groupings of three ses-
sions. ANOVA indicated a signiﬁcant treatment × sex interaction (p < 0.004). Both groups showed treat-
ment effects, with males displaying an increase in errors (p < 0.03) and females a decrease (p < 0.06).
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Figure 5. Effects of the ketanserin challenge in the 16-arm radial maze showing effects on error rates for
working memory (A) and reference memory (B) at three different ketanserin doses (0.5, 1, and 2 mg/kg).
Data represent means and SEs, with values for males and females combined because of the absence of
an interaction of treatment × sex. In (A), ANOVA indicated a main effect of CPF treatment (p < 0.0001) and
an interaction of CPF × ketanserin dose (p < 0.0001). In (B), both terms were also signiﬁcant (p < 0.0001 and
p < 0.002). Because of the interaction of the two treatments, separate analyses were then conducted for
the effects of ketanserin in the control and CPF-treated groups. For both measures, ketanserin had no
significant effect in the controls, whereas it elicited significant increases in errors in the CPF group
(p < 0.0001 for A; p < 0.002 for B). 
*Ketanserin doses that elicited signiﬁcant increases in errors. affected. In contrast, in the CPF group,
ketanserin evoked a significant increase in
both memory parameters, with a relatively
larger effect on working memory (Figure 5A)
than on reference memory (Figure 5B).
Unlike the effects on acquisition, the response
to ketanserin challenge was not sex selective
(no interaction of ketanserin × sex).
Discussion
Animal models of depression that encompass
deﬁciencies in 5HT synaptic function display
a uniform set of behavioral parallels: locomo-
tor hyperactivity and increased open-arm
time in the elevated plus maze, anhedonia in
the chocolate milk consumption test, and
cognitive impairment; all of these resolve with
therapies that restore 5HT function to nor-
mal (Cairncross 1984; Cryan et al. 1999;
Harkin et al. 1999; Jesberger and Richardson
1985; Juckel et al. 2003; Kelly et al. 1997;
Kusserow et al. 2004; Leonard and Tuite
1981; Mar et al. 2000; Martin et al. 1998;
McGrath and Norman 1999; Pucilowski
et al. 1993; Richardson 1991; Slotkin et al.
1999). In the present study, essentially the
same pattern of behavioral defects was
obtained with CPF exposure in the early
neonatal period, a treatment similarly shown
to produce long-term alterations in 5HT
synaptic proteins commensurate with a reduc-
tion in 5HT function (Aldridge et al. 2004).
Indeed, it is possible to draw a direct connec-
tion between at least one feature of the neuro-
chemical alterations and the corresponding
behavioral effect. CPF exposure evokes
prominent up-regulation of 5HT1A receptors
(Aldridge et al. 2004), and in a recent study,
transgenic animals overexpressing this recep-
tor similarly showed increased open-arm
activity in the plus maze, just as found here
for the CPF group (Kusserow et al. 2004).
Furthermore, the CPF effects on receptor
expression (Aldridge et al. 2004) and behavior
in the plus maze show the same sex selectivity
(effects in males > females). Indeed, because
of the role of 5HT in anxiety (Kusserow et al.
2004), the increase in plus-maze open-arm
activity seen in the CPF-exposed males, an
anxiolytic effect, may be directly attributable
to the loss of 5HT synaptic function.
The sex differences in 5HT synaptic pro-
teins (Aldridge et al. 2004) and in the effects
seen here in the plus maze point to the poten-
tial mechanisms underlying the ability of CPF
to disrupt development and function of 5HT
systems. Both neurochemical and behavioral
findings indicate that, when CPF exposure
occurs during a developmental stage before
sexual differentiation of the brain, there are
no sex differences in the ultimate effects
(Aldridge et al. 2004; Icenogle et al. 2004;
Meyer et al. 2004b; Qiao et al. 2004),
whereas similar treatments targeted to the
peak period of sexual differentiation in late
gestation through the early neonatal period
(McCarthy 1994), produce disparate effects
in males versus females (Aldridge et al. 2004;
Dam et al. 2000; Garcia et al. 2003; Levin
et al. 2001, 2002; Meyer et al. 2004a, 2004b;
Qiao et al. 2003). CPF lacks sufﬁcient estro-
genic activity to account directly for these
effects (Andersen et al. 2002), and although it
interferes with testosterone catabolism
(Usmani et al. 2003) and can elicit secondary
endocrine alterations (Guven et al. 1999), the
doses required for such actions lie above the
threshold for systemic toxicity, unlike the
effects on neurodevelopment. Instead, given
the ability of CPF to disrupt neural cell repli-
cation, differentiation, axonogenesis, and
synaptogenesis (Barone et al. 2000; Casida
and Quistad 2004; Gupta 2004; Pope 1999;
Slotkin 1999, 2004), it is most likely that the
adverse effects of CPF on brain cell develop-
ment themselves contribute to changes in sex-
ual differentiation and resultant sex-related
outcomes. In fact, our results substantiate this
interpretation: in every case where the effects
of CPF showed sex selectivity, the net actions
represented the blunting of normal sex differ-
ences in the corresponding behavior. Thus, in
the elevated plus maze, females normally
show greater locomotor activity and time
spent in the open arms (Elliott et al. 2004),
and CPF obliterated this difference by femi-
nizing the behavior of males, increasing their
scores to those seen in normal females. In
keeping with effects targeting sexual differen-
tiation, the activation of locomotor activity in
males has its onset only after puberty (Dam
et al. 2000). In the same vein, in the 16-arm
radial maze, males ordinarily make fewer
working and reference memory errors than do
females (Icenogle et al. 2004; Levin et al.
2001, 2002), and neonatal CPF exposure
raised the error rate in males and decreased
that of females so that there were no longer
any sex differences. Our results point out the
importance of distinguishing both neuro-
chemical and behavioral outcomes in males
and females, as opposed to the not atypical
practice of examining only males, or of com-
bining results from both sexes without dis-
crimination.
It is important to note that the effects of
CPF are sex selective but not sex speciﬁc; that
is, whereas some of the 5HT neurochemical
(Aldridge et al. 2004) and behavioral (Dam
et al. 2000; Levin et al. 2001) effects are greater
in males than in females, both sexes do show
significant alterations. In the present study,
anhedonia was detected in both sexes, and the
cognitive effects of ketanserin challenge were
similar in males and females. In fact, the latter
test raises an interesting question: If CPF elicits
deficits in 5HT synaptic function, why does
5HT2 receptor blockade increase error rates in
the CPF-exposed animals when it has no such
effect in controls? Here, it is important to note
that, ordinarily, hippocampal cholinergic sys-
tems play a critical role in radial-arm maze per-
formance, and it is these inputs that are
especially targeted by neonatal CPF exposure
(Slotkin et al. 2001), drastically reducing their
contribution to working and reference memory
performance (Levin et al. 2001). CPF-exposed
animals do learn the radial-arm maze but by
alternate, noncholinergic mechanisms (Levin
et al. 2001), and the present results indicate
that 5HT provides one of these critical adapta-
tions. Accordingly, although 5HT function is
deficient, yet at the same time, the CPF-
exposed animals have an atypical reliance on
5HT inputs for behaviors that do not ordinar-
ily depend on this transmitter. In turn, this
may create a situation in which cognitive func-
tion becomes increasingly vulnerable to situa-
tions that compromise 5HT synaptic function,
such as genetic, neurochemical, or external fac-
tors that foster affective disorders. Indeed,
many of the new generation of antidepressant
and antipsychotic medications possess 5HT2
antagonist properties (Anttila and Leinonen
2001; Poyurovsky et al. 2003; Tyson et al.
2004), and our results suggest that early CPF
exposure could lead to a subpopulation that is
vulnerable to cognitive impairment by these
agents, compromising their utility. This would
be particularly important if, as indicated by the
present results, developmental CPF exposure
affects 5HT systems in a manner commensu-
rate with augmented risk of depression, thus
increasing the potential use of antidepressant
medications.
Our results indicate that the long-term
alterations in 5HT synaptic neurochemistry
elicited by otherwise subtoxic neonatal CPF
exposure (Aldridge et al. 2004) are associated
with a pattern of behavioral effects commen-
surate with deficient 5HT function, resem-
bling that seen in animal models of depression
(Cairncross 1984; Cryan et al. 1999; Harkin
et al. 1999; Jesberger and Richardson 1985;
Juckel et al. 2003; Kelly et al. 1997; Kusserow
et al. 2004; Leonard and Tuite 1981; Mar
et al. 2000; Martin et al. 1998; McGrath and
Norman 1999; Pucilowski et al. 1993;
Richardson 1991; Slotkin et al. 1999). Many
of the 5HT-related effects of CPF reﬂect dis-
ruption of neural development during sexual
differentiation of the brain, thus contributing
to disparate effects in males and females.
Nevertheless, deﬁciencies in cholinergic input
to cognitive performance result in an increased
reliance on 5HT mechanisms that are not
ordinarily called into play in normal animals,
increasing the vulnerability to 5HT blockers
or other potential factors that inﬂuence 5HT
activity. It has been suggested that environ-
mental toxicants that trigger long-term alter-
ations in the programming of 5HT function
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ders, and resulting increases in the incidence
of obesity, diabetes, and depression (Slikker
and Schwetz 2003; Toschke et al. 2002;
von Kries et al. 2002). Our results with neona-
tal CPF exposure provide some of the first
support for that hypothesis.
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